骨髓纤维化患者合并膜性肾病与肾内髓外造血一例
本文报告一例63岁原发性骨髓纤维化患者,因肾病范围蛋白尿和肾功能减退行肾活检,发现膜性肾病改变及肾间质、管周毛细血管和肾周组织髓外造血浸润。经肾素-血管紧张素阻断和Janus激酶抑制剂治疗,肾功能和蛋白尿改善。
要点
- 骨髓增殖性肿瘤患者出现肾病范围蛋白尿时需考虑膜性肾病可能
- 肾活检可同时发现肾小球病变和髓外造血浸润
- RAAS阻断联合JAK抑制剂可能改善此类患者的肾功能和蛋白尿
核心结论
- 原发性骨髓纤维化患者可同时发生膜性肾病和肾内髓外造血,RAAS阻断联合JAK抑制剂治疗后肾功能和蛋白尿改善。
研究设计与样本
- 单个病例报告:一例63岁原发性骨髓纤维化患者因肾病范围蛋白尿和肾功能减退接受肾活检。
主要发现
- 肾活检显示系膜硬化及细胞增多,符合膜性肾病改变。
- 肾间质、管周毛细血管和肾周组织可见造血细胞浸润,符合髓外造血。
临床怎么用
- 骨髓增殖性肿瘤患者出现蛋白尿或肾功能减退时应考虑肾活检明确病因。
- 确诊膜性肾病合并髓外造血者,可尝试RAAS阻断联合JAK抑制剂治疗。
局限性
- 单例病例报告,结论不可推广至所有骨髓纤维化合并肾病患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Kidney disease in the setting of a hematologic malignancy is common, with the frequency and type of kidney disease varying depending on the specific malignancy. Various glomerular diseases and tumor infiltration of the kidneys have been reported in patients with lymphoproliferative disorders. Descriptions of kidney involvement in myeloproliferative disorders have been much rarer. We report a case of membranous nephropathy accompanied by kidney injury in a patient with primary myelofibrosis with additional features considered related to the patient's myeloproliferative disorder. A 63-year-old patient with primary myelofibrosis underwent kidney biopsy to investigate nephrotic-range proteinuria and reduced kidney function. Histologic analysis revealed mesangial sclerosis and hypercellularity, changes indicative of membranous nephropathy, and infiltration of hematopoietic cells into the renal interstitium, peritubular capillaries, and perirenal tissue consistent with extramedullary hematopoiesis. He was treated with renin-angiotensin blockade and a Janus kinase inhibitor, resulting in improvement in kidney function and proteinuria.
引用
- Philipponnet C, Ronco P, Aniort J, et al. Membranous Nephropathy and Intrarenal Extramedullary Hematopoiesis in a Patient With Myelofibrosis. Am J Kidney Dis. 2017. PMID: 28821362. doi:10.1053/j.ajkd.2017.06.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。